Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
MyoKardia is a biotechnology business based in the US. MyoKardia stocks (MYOK.US) are listed on the NASDAQ and all prices are listed in US Dollars. MyoKardia employs 318 staff and has a trailing 12-month revenue of around $12.4 million.
|52-week range||$0.00 - $0.00|
|50-day moving average||$224.21|
|200-day moving average||$137.46|
|Wall St. target price||$225.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.57|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||$12.4 million|
|Gross profit TTM||$-226,171,000|
|Return on assets TTM||-23.07%|
|Return on equity TTM||0%|
|Market capitalisation||$12 billion|
TTM: trailing 12 months
We're not expecting MyoKardia to pay a dividend over the next 12 months.
Over the last 12 months, MyoKardia's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MyoKardia's is 1.8348. This would suggest that MyoKardia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MyoKardia, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.